In addition, antibody drug conjugates like trastuzumab-emtansine (T-DM1) are used to specifically kill HER2 positive cancer cells with the conjugated cytotoxic drug emtansine (DM1), while bispecific antibodies are used to attract and activate components of the immune system against HER2 positive tumor cells [10]. The gene discussed is ERBB2; the disease is neoplasm.